Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2021

Mitochondria in epithelial ovarian carcinoma exhibit abnormal
phenotypes and blunted associations with biobehavioral factors
Snehal Bindra
Marlon A. McGill
Marina K. Triplett
Anisha Tyagi
Premal H. Thaker

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Snehal Bindra, Marlon A. McGill, Marina K. Triplett, Anisha Tyagi, Premal H. Thaker, Laila Dahmoush,
Michael J. Goodheart, R. Todd Ogden, Edward Owusu-Ansah, Kalpita R. Karan, Steve Cole, Anil K. Sood,
Susan K. Lutgendorf, and Martin Picard

www.nature.com/scientificreports

OPEN

Mitochondria in epithelial ovarian
carcinoma exhibit abnormal
phenotypes and blunted
associations with biobehavioral
factors
Snehal Bindra1, Marlon A. McGill1, Marina K. Triplett1, Anisha Tyagi1, Premal H. Thaker2,
Laila Dahmoush3, Michael J. Goodheart4, R. Todd Ogden5, Edward Owusu‑Ansah6,
Kalpita R Karan1, Steve Cole7, Anil K. Sood8, Susan K. Lutgendorf4,9,10* &
Martin Picard1,11,12*
Malignant tumor cells exhibit mitochondrial alterations and are also influenced by biobehavioral
processes, but the intersection of biobehavioral factors and mitochondria in malignant tumors
remains unexplored. Here we examined multiple biochemical and molecular markers of mitochondrial
content and function in benign tissue and in high-grade epithelial ovarian carcinoma (EOC) in parallel
with exploratory analyses of biobehavioral factors. First, analysis of a publicly-available database
(n = 1435) showed that gene expression of specific mitochondrial proteins in EOC is associated with
survival. Quantifying multiple biochemical and molecular markers of mitochondrial content and
function in tissue from 51 patients with benign ovarian masses and 128 patients with high-grade EOC
revealed that compared to benign tissue, EOCs exhibit 3.3–8.4-fold higher mitochondrial content
and respiratory chain enzymatic activities (P < 0.001) but similar mitochondrial DNA (mtDNA) levels
(− 3.1%), documenting abnormal mitochondrial phenotypes in EOC. Mitochondrial respiratory chain
activity was also associated with interleukin-6 (IL-6) levels in ascites. In benign tissue, negative
biobehavioral factors were inversely correlated with mitochondrial content and respiratory
chain activities, whereas positive biobehavioral factors tended to be positively correlated with
mitochondrial measures, although effect sizes were small to medium (r = − 0.43 to 0.47). In contrast,
serous EOCs showed less pronounced biobehavioral-mitochondrial correlations. These results
document abnormal mitochondrial functional phenotypes in EOC and warrant further research on the
link between biobehavioral factors and mitochondria in cancer.
Mitochondria play a pivotal role in the growth of malignant tumors (henceforth “tumor” is used to refer specifically to malignant tumors). Mitochondrial function enables tumor cell adaptation to stressful environments,
provides plasticity for tumor growth and survival, confers resistance to apoptotic signaling, and can promote
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metastatic phenotypes1–3. Human tumor cells exhibit altered energy metabolism and metabolic reprogramming
associated with alterations in mitochondrial DNA (mtDNA) and its associated p
 roteins4. Retrograde signaling
from mitochondria to the nucleus can also promote a shift in cellular metabolism towards aerobic g lycolysis5.
Clinically, mitochondrial dysfunction is therefore believed to contribute to tumor p
 rogression6, chemoresistance7,
8,9
and reduced progression-free survival (PFS) . Ovarian carcinoma cells also secrete pro-inflammatory mediators such as interleukin-6 (IL-6) which in turn promote tumor proliferation, invasion, and c hemoresistance10.
Furthermore, metabolic changes in healthy stromal tissue surrounding the tumor (tumor microenvironment)
produce metabolites that promote inflammation and support tumor g rowth11. Therefore, mitochondrial function—both within benign and tumor tissues—represents a potential pathway that may influence tumor behavior
and downstream clinical outcomes.
A substantial body of research over the last 30 years documents relationships between biobehavioral factors
and cancer progression. Biobehavioral pathways—referring collectively to behavioral, social, and/or psychological
factors and concomitant biologic processes—can directly affect neuroendocrine signaling pathways to enhance
tumor growth and impair the immune response in c ancer12. Specifically, psychological stress, beta-adrenergic,
and glucocorticoid signaling have been shown to enhance processes such as angiogenesis, tumor cell invasion,
and resistance to anoikis, representing additional pathways that promote tumor growth and metastasis13,14.
Biobehavioral factors also have indirect effects on tumors via effects on host cells in the tumor microenvironment
such as macrophages or fibroblasts that can be repurposed to promote tumor g rowth12,15,16. Collectively, these
data suggest the existence of biological mechanisms to translate positive and negative psychosocial experiences
into molecular changes within tumors.
Mitochondria have been shown to dynamically respond to biobehavioral processes and to be functionally
linked to the major neuroendocrine and immune pathways that are known to be modulated by psychological
states17–19. This includes glucocorticoid stress hormones released during psychosocial stress and their associated
metabolic effects20. A systematic review of the literature revealed consistent effects of chronic mental stress on
mitochondria including mitochondrial content and the activity of respiratory chain complexes involved in energy
transformation21. In mitochondria, both the respiratory chain involved in energy production and macromolecule
biosynthesis, as well as the maintenance of the mitochondrial genome, can be a target of biobehavioral processes.
Considering both these genetic and biochemical aspects, we recently developed a high-throughput approach
to simultaneously monitor i) mitochondrial content and ii) functional capacity in human blood leukocytes22.
Using this approach in parallel with daily biobehavioral assessments revealed that mood is associated with mitochondrial functional capacity on subsequent days22. Moreover, acute mental stress that induces negative mood
can also lead to the release of the potentially immunogenic circulating cell-free mtDNA (cf-mtDNA) in plasma
and serum within minutes 23,24, providing further evidence that mitochondria in normal (i.e., non-cancerous)
tissues functionally respond to biobehavioral factors.
Here, to examine the potential relevance of mitochondrial function in ovarian cancer, we first surveyed a
publicly-available ovarian cancer gene expression dataset. We characterized multiple biochemical and molecular
markers of mitochondrial content and function in non-cancerous tissue and tissue from ovarian carcinomas,
in parallel with inflammation. To explore whether mitochondrial remodeling represents a potential pathway by
which biobehavioral processes may support tumor growth and progression, we also quantified the association
of biobehavioral factors and mitochondrial phenotypes in epithelial ovarian carcinomas (EOC) or benign tissue.

Results

Mitochondrial gene expression and survival. We first leveraged a publicly available gene expression
dataset, Kaplan Meier Plotter25,26, to examine whether ovarian cancer outcomes, such as survival, are associated
with the expression of mitochondrial genes. Low levels of a major regulator of mitochondrial metabolism, the
mitochondrial pyruvate carrier (MPC2), are known to promote metabolic reprogramming and are associated
with greater mortality when MPC is removed in cells and preclinical models27. Initial analyses included patients
with different histological subtypes, stages, and grades of EOC. Among 614 women with ovarian cancer cases
followed over 20 years, we found that relative to those with high MPC2 gene expression, low MPC expression
was associated with a 59% increase in mortality (p < 0.0001, Fig. 1A), suggesting that mitochondrial metabolism
contributes to ovarian tumor biology in humans.
We then extended this analysis to genes encoding subunits of the respiratory chain complexes I-V, which are
involved in mitochondrial oxidative p
 hosphorylation28. Similar to MPC2, we generated Kaplan–Meier curves
for each available gene encoding a subunit of respiratory chain complexes I through V. The expression levels
of respiratory chain subunits, as well as mtDNA maintenance genes, were variably associated with mortality
(Fig. 1B-G). Compared to a set of randomly selected genes (false discovery rate: 58.5%), the proportion of subunits significantly associated with mortality was higher for complexes II, III and mtDNA-related genes (Fig. 1H).
Sensitivity analyses restricting data to high grade patients performed on expression of MPC2, complex II, and
mtDNA-related genes yielded similar results (data not shown). Together, these epidemiological, longitudinal data
indirectly suggested that ovarian cancer biology in humans may be modulated by metabolic and mitochondrial
factors.
Mitochondrial phenotyping in ovarian tumors. To examine the link between mitochondrial respira-

tory chain function and ovarian cancer outcomes more directly, we then analyzed tissue from high-grade EOC
(n = 128) and benign ovarian masses (n = 51) collected during surgery (Fig. 2A). EOCs were histologically identified as serous, endometrioid, mucinous, or clear cell, with the majority (78.1%) being serous. All tumors were
high grade. Benign masses were of epithelial and stromal histology.
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Figure 1.  Expression of mitochondrial genes predict survival in ovarian cancer patients. (A) Kaplan Meier
Plotter (KMPlot.org) survival analysis of patients with ovarian cancer exhibiting low (n = 454) or high (n = 160)
gene expression for a key component of mitochondrial metabolism, the mitochondrial pyruvate carrier 2
(MPC2) gene. (B) Hazard ratios (HR) from Kaplan Meier survival analysis shown as forest plots for genes
encoding subunits of the mitochondrial respiratory chain complexes I, (C) II, (D) III, (E) IV, (F) V, and (G) and
mtDNA-related genes. (H) Summary of results illustrating the proportion of significant subunits in previous
analysis relative to results from a randomly selected group of 200 genes. Shown are mean HR with 95% C.I.
established based on the optimal cutoff; n = 614–1435 for each gene. Filled symbols are significant based on the
95% C.I.
To account for possible tumor heterogeneity in the enzymatic and molecular analyses, two partitions of each
sample were processed in parallel, measured in triplicate, and the average taken to reflect each ovarian sample most robustly. Our approach included parallel measurements of enzymatic activities for respiratory chain
complexes II (succinate dehydrogenase, SDH) and IV (cytochrome c oxidase, COX) reflecting mitochondrial
respiratory chain capacity, as well as citrate synthase (CS) and mtDNA copy number (mtDNAcn) reflecting mitochondrial content (Fig. 2B). On average, in EOC the mitochondrial enzymes were moderately correlated with
each other, sharing 20.3–47.3% of their variance, whereas mtDNAcn was minimally correlated with enzymatic
activities (1.1–3.4% of shared variance). These data suggest that each mitochondrial marker contributes different
information about the tumor mitochondrial phenotypes and that mtDNAcn is likely regulated independently
from enzymatic measures. Age was examined as a possible factor that might influence mitochondrial function.
Enzymatic activities and mtDNAcn in EOC were minimally associated with age ( r2 = 0.00–0.078), such that < 8%
of the variation in mitochondrial content and function was attributable to age in this cohort. The results were
similar for associations of enzymatic activities and mtDNAcn with age in benign tissue ( r2 = 0.00–0.043).
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Figure 2.  Mitochondrial profiling in benign and epithelial ovarian carcinoma (EOC) tissue. (A) Overview
of the study design illustrating the multi-level approach ranging from biobehavioral factors to biochemical
and molecular assessments of mitochondrial content and function. (B) Schematic of the internal components
of the mitochondrial respiratory chain (complexes I-V), the tricarboxylic acid (TCA, also Krebs) cycle,
and the mitochondrial genome (mtDNA). Enzymatic activities measured include citrate synthase (CS),
succinate dehydrogenase (SDH, complex II), and cytochrome c oxidase (COX, complex IV). mtDNA copy
number (mtDNAcn) was measured using qPCR. Using this data, the Mitochondrial Health Index (MHI) was
calculated for each patient with mean-centered activities of respiratory chain complexes, divided by markers
of mitochondrial c ontent3. (C) Enzymatic activities for CS, SDH, and COX, (D) mtDNAcn, and (E) MHI. (F)
Average COX/SDH ratio and (G) scatterplot illustrating the distinct mitochondrial phenotypes between benign
vs EOC. Each data-point represents the average of two measures for a participant; graphed on Log10 scale.
n = 51 benign, n = 128 high-grade EOCs, P values from one-way ANOVA performed on log-transformed data.
*** p < 0.001. The non-transformed data is shown.

Mitochondrial content and function are elevated in EOC relative to benign. We first compared

mitochondrial measures between high-grade EOC tissue and benign ovarian masses. Relative to benign tissue,
ovarian tumors exhibited a striking 8.4-fold higher CS activity, 3.3-fold higher SDH activity, and a 8.2-fold
higher COX activity (Fig. 2C), but a similar (3.1% lower, N.S.) mtDNAcn (Fig. 2D). The mitochondrial health
index (MHI), a computed metric representing the ratio of respiratory chain activity (SDH and COX) divided
by markers of mitochondrial content (CS and mtDNAcn)22, was also double in EOC compared to benign tissue
(Fig. 2E). Because SDH is uniquely encoded in the nuclear genome, whereas COX is partially mtDNA-encoded,
we also computed the ratio of both enzymes (Fig. 2F), which can be indicative of abnormal mitochondrial
phenotypes29. Here the COX/SDH ratio was approximately 3 times higher in EOC. Plotting each tumor and
benign sample in a bi-plot showed fairly good separation between both groups, indicating a possible imbalance
or recalibration of the respiratory chain components in tumor tissue (Fig. 2G). Moreover, the minimal decline in
mtDNAcn in light of the approximately 3.3–8.4-fold higher mitochondrial mass means that the mitochondrial
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Figure 3.  Mitochondrial phenotyping across EOC histologic subtypes and benign tissue. (A) EOC histologic
subtypes included in this study. (B) Mitochondrial enzymatic activities, (C) mtDNAcn, and (D) MHI by tumor
stage. Data are means ± SEM. (E) Enzymatic activities, (F) mtDNAcn, and (G) MHI values by EOC histologic
subtype shown as violin plots with each datapoint representing an individual patient. P values from one-way
ANOVA performed on log-transformed data. The non-transformed data is shown.
genome density (mtDNA/CS) per mitochondrion is dramatically reduced in tumors. Together, these findings
demonstrate that beyond gross changes in mitochondrial abundance, tumor mitochondria exhibit abnormal
mitochondrial phenotypes that are qualitatively different from benign tissue.

Mitochondrial content and function across tumor stages and types. Overall, EOC presented
with a broad range of mitochondrial enzymatic activities and mtDNAcn (Fig. 3A-B). Average respiratory chain
enzyme activities were approximately equivalent in Stages I through III and then decreased substantially by
Stage IV. For CS, SDH, and COX, metastatic tumors (Stage IV) showed approximately half (55.8–61.9%) the
enzymatic levels of stage I tumors, although these differences were non-significant (p values > 0.05) due to high
variation within each stage. mtDNAcn of Stage IV tumors was on average 28.2% lower than in Stage I tumors, or
half of the magnitude of differences between stages I and IV observed for enzymatic activities) (Fig. 3C), again
suggesting that mtDNAcn may be regulated independently from enzymatic components. The MHI did not differ
statistically across stages (Fig. 3D).
Next, we compared mitochondrial measures across several EOC histological subtypes. This revealed two main
points: (1) there is large inter-individual variation in enzymatic activities even within the same tumor type; and
(2) there are potentially large differences in activities between tumor histologies (Fig. 3E-G), although this study
was not powered to detect these differences.
Tumor mitochondrial parameters and IL‑6. Mitochondrial function is linked to pro-inflammatory
signaling and cytokine production, including interleukin 6 (IL-6)30,31 and IL-6 signaling may influence tumorpromoting processes such as a ngiogenesis32. Therefore, to evaluate whether mitochondrial measures are related
to the pro-inflammatory phenotype, we measured IL-6 levels in ascites and plasma from participants with EOC,
across all stages, and systematically tested their association with tumor mitochondrial respiratory chain enzymatic activities and mtDNAcn (Fig. 4A). Tumor mitochondrial respiratory chain activity and content, particularly the integrated metric MHI (Fig. 4B), were consistently negatively correlated with IL-6 levels in ascites
(p values = 0.042 to < 0.001); moreover correlations were up to an order of magnitude larger in ascites than in
plasma. In contrast, mtDNA density per mitochondrial unit (ratio of mtDNAcn/CS) was correlated positively
with ascites IL-6 (p value = 0.014) (Fig. 4C), possibly reflecting the pro-inflammatory intracellular signaling
effects of mtDNA33,34.
Associations between biobehavioral factors and mitochondrial phenotypes. Because serous
tumors are the predominant tumor type in ovarian cancer, we focused analyses with biobehavioral factors on
high-grade serous EOC. These exploratory analyses examined whether mitochondrial parameters were associated with negative and positive biobehavioral factors. Negative biobehavioral factors were moderately intercorrelated, sharing between 14.9 and 51.9% of their variance, and the proportion of shared variance among
positive biobehavioral factors ranged from 0.003 to 42.1%, indicating no co-linearity to moderate co-linearity
between these variables. The strength and direction of each mitochondria-biobehavioral correlation is displayed
as a heat map in Fig. 5A and with 95% confidence intervals shown for the enzymatic mitochondrial measures
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Figure 4.  Mitochondrial measures and IL-6 in high-grade epithelial ovarian carcinoma. (A) Pearson
correlations between mitochondrial measures and IL-6 levels measured in ascites and plasma. Note the similar
patterns of correlation between ascites and plasma, and the contrast in the associations between mtDNA-related
measures (positive) and primary measures of mitochondrial content and respiratory chain function (negative).
(B) Scatterplots of the correlations between ascites IL-6 levels and the mitochondrial health index (MHI), and
(C) mtDNA density per mitochondrion (mtDNAcn/CS). n = 50–64 for ascites, 82–110 for plasma.
(CS, SDH, COX) in Fig. 5B. These results suggest patterns of association with relatively small to moderate effect
sizes (range: r = − 0.43 to 0.47) across multiple mitochondrial measures and biobehavioral assessments, leading
to three main observations.
First, in benign tissues, negative biobehavioral measures such as depression, fatigue, and negative mood
tended to be generally associated with lower levels of mitochondrial enzymatic activities. Fatigue was the measure
most consistently related to mitochondrial activity, with effect sizes in the moderate range for all mitochondrial
enzymes, and significant negative associations with COX r = − 0.38, p = 0.04 and MHI r = − 0.40, p = 0.039 and
positive associations with mtDNA/CS r = 0.37, p = 0.059. In contrast, positive biobehavioral measures such as
vigor, well-being, and positive mood tended to be positively correlated with mitochondrial parameters, although
only the relationship between social attachment and COX reached statistical significance, r = 0.47, p = 0.004.
Although these relationships were not generally statistically significant due to the small sample size in many
of these analyses (n = 27–36), we note an apparent consistency in their direction across primary mitochondrial
measures (CS, SDH, COX). This would seem to be consistent with previous findings in blood leukocytes22, and
these observations should be examined further in more strongly powered studies.
Second, in benign tissue, compared to the associations seen in respiratory chain enzymes, associations
between biobehavioral factors and mtDNAcn appear to be in directions opposite to those noted above. This
would be consistent with the existence of independent mechanisms linking biobehavioral factors to mtDNAcn
and respiratory chain function.
Third, in contrast to the apparent biobehavioral-mitochondrial associations in benign tissue, these associations in high grade serous EOC tended to be smaller in magnitude (see Fig. 5B). In EOC, contrary to expectation,
both positive and negative factors were associated with higher levels of respiratory chain enzymes (depressive
mood and COX: r = 0.26, p = 0.014; quality of life and SDH (r = 0.29, p = 0.009); well-being and SDH (r = 0.28,
p = 0.050). Interestingly, biobehavioral characteristics indicating positive affect (Center for Epidemiologic Studies Depression Scale-positive subscale [CESD-positive], Profile of Mood States vigor subscale [POMS-vigor]),
which may be more fleeting, were not strongly associated with respiratory chain enzymes. In contrast, the positive dimensions of quality of life and well-being which may reflect a more sustained positive orientation, were
significantly associated with higher levels of respiratory chain activity in tumor tissue.

Discussion

In this study of epithelial ovarian cancer, we examined multiple enzymatic and molecular mitochondrial measures, and the intersection of mitochondrial biology and biobehavioral factors. After interrogating mitochondrial
gene expression from a large database of ovarian cancer survival as proof-of-concept of the significance of
mitochondria in ovarian tumor biology, we leveraged a high-throughput mitochondrial phenotyping platform
to measure markers of mitochondrial content and function. In parallel, to investigate whether mitochondrial
remodeling represents a potential pathway by which biobehavioral processes may support tumor growth and
progression, we analyzed several domains of psychosocial functioning in ovarian cancer patients at the time of
surgery. From a tumor biology perspective, our mitochondrial respiratory chain and mtDNA results demonstrate
striking differences in mitochondrial phenotypes between tumor and benign tissues, and suggest potential differences among different histologies and tumor stages. Our exploratory analyses also suggest relatively blunted
associations between biobehavioral factors and mitochondria in high grade serous EOC, in comparison with
benign tissue where positive and negative biobehavioral measures are potentially more strongly related to mitochondrial function. This is the first study to examine the association of biobehavioral factors with mitochondrial content and function in cancer. Overall, these findings extend pre-clinical work suggesting mitochondrial
reprogramming in ovarian cancer in humans.
The extension of pre-clinical findings concerning the influence of MPC2 on mitochondrial metabolism and
tumor growth27 to MPC2 gene expression and survival in women with EOC provides proof-of-concept that
mitochondrial (dys)function may contribute to clinical outcomes. In systematically broadening the search to
other mitochondrial components, one of the striking observations from the gene expression-survival analysis
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Figure 5.  Associations of biobehavioral factors with mitochondrial content and function in high-grade serous
epithelial ovarian carcinoma (EOC) and in epithelial and stromal benign tissues. (A) Correlations between
negative/positive biobehavioral factors and markers of mitochondrial content (CS, mtDNAcn), mitochondrial
respiratory chain enzymatic activities (SDH, COX), and mtDNAcn density (mtDNAcn/CS). Results are Pearson
correlation coefficients illustrated in a heatmap, generated through Prism 8 (Graphpad), depicting the direction
(color) and strength (saturation) of the associations. Benign and high-grade serous EOC tissues may have
opposite associations among biobehavioral factors and mitochondrial activity particularly for CS and respiratory
chain complexes II (SDH) and IV (COX). Center for Epidemiologic Studies Depression Scale (CESD);
Profile of Mood States (POMS); Social Provisions Scale (SPS), Functional Assessment of Cancer TherapiesGeneral (FACT-G) (B) Effect sizes shown in A for the primary enzymatic measures (CS, SDH, COX) with
95% confidence intervals. Whereas data from subscales and scales are presented in A, overlapping scales and
subscales are omitted from this panel. Correlation coefficients determined from log-transformed data. n = 22–36
benign, n = 37–91 EOC; correlations are Pearson r from log-transformed values.
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(Fig. 1) is the heterogeneity in the direction of the associations for proteins belonging to the same complex. To
our knowledge, this has not previously been examined in detail. For example, higher expression of NDUFAF2
was associated with lower mortality. NDUFAF2 is a complex I assembly factor that is required for synthesizing
the part of complex I that protrudes in the mitochondrial matrix and binds NADH (N module) produced by the
Krebs cycle. Paradoxically, we find that an elevated expression of many of the structural complex I subunits that
are part of the N module is associated with higher mortality. This may be due to the fact that when such subunits
are overexpressed in the absence of a concomitant overexpression of NDUFAF2, they interact with other proteins
to disrupt other signaling networks. For instance, NDUFV1 interacts with LRRK235, and NDUFS1 interacts with
the iron-sulfur cluster co-chaperone protein H
 scB36; hence it is conceivable that when overexpressed they bind
and sequester HscB to the point that other cellular processes dependent on iron-sulfur clusters are compromised.
Similarly, NDUFS6 interacts with BOLA3, which also regulates iron-sulfur cluster b
 iogenesis37 while NDUFS4
interacts with proline-rich transmembrane protein 2 (PRRT2)38. In relation to mtDNA, higher expression of
both isoforms of ATAD3 (ATAD3A and ATAD3B), which are likely involved in cholesterol metabolism in addition to mtDNA nucleoid r egulation39, is associated with > 50% increase in mortality. In contrast, expression
of both TFAM and the mitochondrial RNA polymerase, which both promote mtDNA gene expression40, are
negatively associated with mortality. Thus, as expected from known protein–protein interactions, these data also
demonstrate that different respiratory chain subunits belonging to the same protein complexes could have vastly
different influence on tumor biology depending upon their specific molecular interactions and position within
multi-protein respiratory chain complexes.
One point of interest relates to mitochondrial content (CS and mtDNAcn) which was found to be exceptionally high in EOC relative to benign tissue. While some studies have reported a decrease in SDH and COX
activity in breast and renal c arcinomas42, we report increased activity in EOC compared to healthy tissue. CS
upregulation has been observed in other ovarian cancer studies41. In cancer cells, mitochondria are biosynthetic
centers—several aspects of their function, including the respiratory chain and associated Krebs cycle enzymes,
are diverted to provide biosynthetic products to support cell growth6,43 (reviewed in44). The upregulation of
CS might be responsible for regulating citrate levels and affecting cellular lipid synthesis, which drives key
cellular processes such as transformation, tumor development, and disease progression45. Citrate, like other
mitochondria-derived metabolites with pro-oncogenic effects46, is considered an oncometabolite42. Other known
mitochondrial metabolites accumulated in tumors can also activate oncogenic signaling cascades, including
succinate and fumarate that are the substrate and product, respectively, of the reaction catalyzed by SDH46,47,.
As increased CS and SDH activity would result in an increase in citrate and fumarate, our findings indicating a
significant increase in CS and SDH activities in tumor compared to benign mitochondria suggest that this may
be worth examining in future studies. More generally, increased mitochondrial mass could be the product of
increased biogenesis, decreased autophagic removal of mitochondria, or a combination of these and other factors. In support of this point, mitochondrial biogenesis has been observed in various human tumor types and
correlates with metastatic b
 ehavior48 and poor clinical outcomes2.
Another unresolved point relates to the association between mitochondrial content and function with IL-6.
Besides abnormal mitochondrial metabolism, inflammation is another biological hallmark of tumor transformation and progression49. In patients with EOC, we noted a negative association between mitochondrial
enzyme activities and IL-6 levels in ascites. In circulating blood, these associations were in the same direction as
ascites but less robust, consistent with the tumors being the primary source of IL-650 and the “leakage” of IL-6
into circulation. Our data suggest a fairly robust negative association between both mitochondrial mass and
respiratory chain function and IL-6. This apparent anti-inflammatory phenotype of mitochondria-rich tissues
could be explained by a number of mechanisms that require further work to confirm. One possibility is that this
association reflects some crosstalk between tumor mitochondria and resident immune c ells51,52. Consistent with
our data, the upregulation of mitochondrial biogenesis (higher mitochondrial mass, respiratory chain activity)
promotes an anti-inflammatory shift in monocytes53. Acute perturbations of mitochondrial respiratory chain
function also alter cytokine production in human leukocytes54, substantiating the link between mitochondrial
function and cytokine production in human immune cells. Together, these data suggest that the mitochondrial
phenotype may influence the inflammatory state, rather than the other way around. However, further work is
needed to test this proposition in EOC.
There is a need to establish biologically plausible pathways linking psychosocial experiences with human
health outcomes55. Here, the exploratory associations between biobehavioral and mitochondrial measures suggest that compared to benign tissue, EOC may respond differently to negative psychosocial factors. Benign tissue
appeared to have similar associations to those we have previously reported in leukocytes in response to positive
and negative biobehavioral f actors22. Specifically, in our previous work, positive mood (more so than negative
mood) was significantly associated with future mitochondrial respiratory chain function (i.e., MHI)22. While the
basis for any such difference remains unclear, we speculate that abnormal mitochondrial phenotypes in tumors
may render tumor mitochondria less responsive to the natural influence of neuroendocrine factors believed to
mediate the effects of psychosocial factors in other cell t ypes12. However, on the basis of small effect sizes that are
largely not statistically significant, we hesitate to draw definite conclusions, and we advocate for further, more
adequately-powered studies to examine this question.
Contrary to observations involving mitochondrial content and respiratory chain activity, mitochondrial
genome abundance (mtDNAcn), particularly when expressed as mtDNA density per mitochondrion (relative to
mitochondrial mass, mtDNAcn/CS), was found to be positively correlated with ascites IL-6 levels. This antagonistic association of mitochondrial respiratory chain components and mtDNAcn with IL-6 is similar to our
findings with biobehavioral factors. Interestingly, mtDNA instability can cause its release in the cytoplasm and
extracellular space where it is potentially recognized as foreign (i.e., bacterial) by innate immune response systems, triggering the production of antiviral and pro-inflammatory c ytokines56,57. Although it was not possible
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to measure levels of cf-mtDNA in the current study, our data suggest that mtDNA signaling could, in ovarian
cancer, have pro-inflammatory effects. The origin of this opposite association between respiratory chain components and mtDNAcn with both inflammation and biobehavioral outcomes remains unclear but emphasizes
the notion that respiratory chain function and mtDNAcn are not equivalent markers of mitochondrial function.
Overall, our results demonstrate abnormal mitochondrial phenotypes in ovarian tumors and open new
questions related to the role of mitochondrial biology in EOC, including tumor sensitivity to biobehavioral
factors. As mitochondrial dysfunction is directly implicated in several chemoresistance pathways7, future work
may also examine how altered mitochondrial functioning may contribute to clinically relevant processes such
as chemoresistance and clinical outcomes.

Methods

Publicly available ovarian cancer gene expression dataset. To examine the association between
tumor gene expression and progression-free survival, we queried Kaplan Meier Plotter (http://kmplot.com) to
compute the survival over time in 1435 ovarian cancer patients. Kaplan Meier Plotter is the largest publicly available dataset of microarray-based gene expression in 21 different cancer types, including ovarian cancer. Analyses
were not restricted to different subtypes (histology, stage, grade, TP53 mutation) or to treatment groups (debulk,
chemotherapy). We analyzed the prognostic value of transcript level for genes encoding mitochondrial respiratory chain subunits of complexes I through V, as well as genes related to mtDNA maintenance and stability.
Patients were divided into two groups of high and low gene expression using default settings to establish the
optimal threshold as a cutoff. The two groups were compared on progression-free survival over follow up periods of up to 20.8 years. To obtain an unambiguous expression estimate for each gene, the optimal probe selected
based on the JetSet algorithm58 was selected to represent each gene. A survival plot was then generated for
each gene with sample sizes varying according to the gene data available (n = 614–1435 for each gene). The KM
survival estimates and log-rank tests statistic were used to determine the hazard ratio, 95% CI and p-value for
each gene, and the data plotted as forest plots to visualize the direction and magnitude of associations between
complex-specific genes and progression-free survival. To obtain an estimate of false discovery rate in this dataset, we randomly selected 200 genes (“null set”) out of the total 15,000 available human genes. We obtained the
hazard ratios and 95% confidence interval for each random gene and computed the proportion of significant
genes with these parameters, which serves as a reference to evaluate the proportion of significant genes in each
mitochondrial respiratory chain complexes and mtDNA-related genes. Sensitivity analyses restricting the data to
high grade patients (KMPlotter grades 2 and 3) were then conducted on MPC2 and Complex II- and mtDNAassociated genes which showed > 70% significant associations with survival compared to the null set.
Clinical data. Participants were part of a larger study of biobehavioral factors and tumor progression in
ovarian cancer who were prospectively recruited at an initial clinic visit pre-surgery/treatment initiation at 2
large Midwestern hospitals between 12/03 and 8/14. All procedures were IRB approved and all participants
signed informed consents. All human subjects were approved by the Institutional Review Boards at the University of Iowa and Washington University and all research was performed in accordance with relevant guidelines
and regulations.
Inclusion/exclusion. Participants over 18 years old with a newly-diagnosed, histologically-confirmed, primary
invasive epithelial ovarian, peritoneal, or fallopian tube carcinoma or a tumor suspected for ovarian cancer
which turned out to be benign were eligible for inclusion in the parent study. Primary cancers of another organ,
non-epithelial ovarian tumors, tumors of low malignant potential, previous cancer, use of systemic steroid medication in the last 4 months, or comorbidities known to influence the immune response were excluded. For the
current analyses, only high grade ovarian tumor tissue was included, and benign tissue was restricted to epithelial (e.g. cystadenoma) and stromal (e.g. fibroma) histology.
Procedures. Psychosocial assessments were completed at home prior to surgery or initiation of treatment and
clinical data was obtained from medical records. Tissue samples were obtained from primary surgeries conducted prior to beginning of treatment and were flash frozen in liquid nitrogen immediately upon acquisition.
Tissue was available from 128 patients subsequently diagnosed with high-grade EOC and from 51 patients with
benign epithelial or stromal pelvic masses. Plasma was obtained immediately prior to surgery and ascites was
obtained from surgery. Both were frozen at -80 °C until analysis.

Psychosocial measures. The Center for Epidemiological Studies Depression Scale (CESD) contains 20
items assessing frequency of depressive symptoms over the past week59,60. Scores of 16 or higher are indicative
of clinical depression. Four validated subscales have been described and associated with physiological variables
in previous ovarian cancer research59,60. In this study, we used the total score, and the depressed mood, positive
mood, and vegetative subscales.
The Profile of Mood States short form (POMS) includes 37 adjectives describing mood over the last month.
Six factors are included in this measure: anxiety, dysphoria, anger, vigor, fatigue, and confusion. A total distress
score (total mood disturbance: TMD) is derived from the sum of the 5 negative mood factors minus the vigor
subscale. The POMS short form is well-validated, has strong psychometric properties, and is commonly used
for assessment of distress in cancer populations61. Here, in addition to the total scale, we used the fatigue and
vigor scales as ways of examining energy/vitality levels that might be associated with mitochondrial activity.
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The Social Provisions Scale (SPS) is a 24-item self-report scale measuring an individual’s perceptions of their
social support62. Here we use the attachment subscale which has shown strong associations with physiological
measures in previous studies of female cancer p
 atients63.
The Psychological Well-Being Scale measures perceived psychological well-being64. We administered 4 of
the 6 subscales (purpose in life, environmental mastery, personal growth, and self-acceptance) thought to be
particularly relevant for individuals with chronic health challenges. We used the 7-item version of the scales,
with higher scores indicating greater well-being.
The Functional Assessment of Cancer Therapy (FACT-G) is a well-validated and psychometrically sound
27-item scale assessing 4 facets of quality of life (physical, emotional, functional, and social well-being) experienced by cancer patients during the previous week. Higher scores indicate better quality of l ife65.

Mitochondrial content and function. Tissue preparation. Tissue samples were flash frozen and stored

in liquid nitrogen until processing. For each sample, two partitions of 50–65 mg were cut with a scalpel on
a clean, cooled surface. The partitions were allowed to thaw and were mechanically minced on ice. Minced
samples were placed on dry ice and stored at − 80 °C until homogenization in batches. To account for potential
tumor heterogeneity, enzymatic activities and mtDNAcn were measures on each partition individually and the
average of both partitions was calculated, producing a single, more stable value for each tumor and benign sample. Pre-cut tissue samples were mechanically homogenized with Tungsten beads (Cat #69,997) in homogenization buffer containing 1 mM EDTA and 50 mM triethanolamine (pH 7.4) 1:20 (1 mg/20 µl), using a robotized
TissueLyser II (Qiagen) with a 1-min run (30 cycles/sec) followed by an incubation on ice for 5 min, repeated for
a total of three runs. Samples were vortexed before each assay to ensure homogeneity.

Mitochondrial enzymatic activity assays. Mitochondria enzyme activities were quantified spectrophotometrically for citrate synthase (CS), cytochrome c oxidase (COX, complex IV), succinate dehydrogenase (SDH, complex II), and NADH dehydrogenase (complex I). For each assay, 20 ul of homogenate was added per reaction. All
assays were performed at 30 °C. Citrate synthase (CS) activity was measured by detecting the increase in absorbance at 412 nm, in a reaction buffer (200 mM Tris, pH 7.4) containing acetyl-CoA 0.2 mM, 0.2 mM 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB), 0.55 mM oxaloacetic acid, and 0.1% Triton X-100. Final CS activity was
obtained by integrating OD412 change from 120 to 300 s, and by subtracting the non-specific activity measured in
the absence of oxaloacetate. Cytochrome c oxidase (COX, or complex IV) activity was measured by detecting the
decrease in absorbance at 550 nm at 30 °C, in a 100 mM potassium phosphate reaction buffer (pH 7.5) containing 0.1% n-dodecylmaltoside and 100uM of purified reduced cytochrome c. Final COX activity was obtained
by integrating O
 D550 change over 100–350 s and by subtracting spontaneous cyt c oxidation without cell lysate.
Succinate dehydrogenase (SDH, or complex II) activity was measured by detecting the decrease in absorbance at
600 nm at 30 °C, in potassium phosphate 100 mM reaction buffer (pH 7.5) containing 2 mM EDTA, 1 mg/ml
bovine serum albumin (BSA), 4 μM rotenone, 10 mM succinate, 0.25 mM potassium cyanide, 100 μM decylubiquinone, 100 μM DCIP, 200 μM ATP, 0.4 μM antimycin A. Final SDH activity was obtained by integrating
OD600 change over 200–600 s and by subtracting activity detected in the presence of malonate (5 mM), a specific
inhibitor of SDH. NADH dehydrogenase (complex I) activity was measured by detecting the decrease in absorbance at 600 nm at 37 °C, in potassium phosphate 100 mM reaction buffer (pH 7.5) containing 2 mM EDTA, 3.5
mg/ml bovine serum albumin (BSA), 0.25 mM potassium cyanide, 100 μM decylubiquinone, 100 μM DCIP,
200 μM NADH, 0.4 μM antimycin A. Final complex I activity was obtained by integrating O
 D600 change over
200–440 s and by subtracting activity detected in the presence of rotenone (500 μM) and piericidin A (200 μM),
specific inhibitors of complex I. Activities for complex I were too low and were not used for analyses. The molar
extinction coefficients used were 13.6 L m
 ol-1 cm-1 for DTNB, 29.5 L mol−1 cm−1 for reduced cytochrome c, and
16.3 L mol−1 cm-1 for DCIP. Samples were lysed for 10 h at 55 °C, followed by inactivation at 95 °C for 10 min.
The lysate was directly used as template DNA for measurements of mtDNA copy number.
mtDNA copy number. The same homogenate used for enzymatic measurements (10ul) was lysed in lysis buffer
containing 100 mM Tris HCl pH 8.5, 0.5% Tween 20, and 200ug/ml proteinase K (10 h at 55 °C, and used directly
for qPCR-based measurements of mtDNA copy number. qPCR reactions were setup in triplicates using a liquid
handling station (ep-Motion5073, Eppendorf) in 384 well qPCR plates. Duplex qPCR reactions with Taqman
chemistry were used to simultaneously quantify mitochondrial and nuclear amplicons in the same reactions.
Master Mix1 for ND1 (mtDNA) and B2M (nDNA) included: TaqMan Universal Master mix fast (life technologies #4,444,964), 300 nM of custom design primers and 100 nM probes (ND1-Fwd: GAGCGATGGTGAGAG
CTAAGGT, ND1-Rev:CCCTAAAACCCGCCACATCT,Probe: HEX-CCATCACCCTCTACATCACCGCCC
-3IABkFQ.B2M-Fwd: CCAGCAGAGAATGGAAAGTCAA, B2M-Rev: TCTCTCTCCATTCTTCAGTAAGTC
AACT, Probe: FAM-ATGTGTCTGGGTTTCATCCATCCGACA-3IABkFQ). Master Mix2 for COX1 (mtDNA)
and RNaseP (nDNA) included : TaqMan Universal Master Mix fast, 300 nM of custom design primers and 100
nM probes (COX1-Fwd: CTAGCAGGTGTCTCCTCTATCT, COX1-Rev: GAGAAGTAGGACTGCTGTGAT
TAG, Probe: FAM-TGCCATAACCCAATACCAAACGCC-3IABkFQ. RnaseP-Fwd: AGATTTGGACCTGCG
AGCG, RNaseP-Rev: GAGCGGCTGTCTCCACAAGT, Probe: FAM-TTCTGACCTGAAGGCTCTGCGCG3IABkFQ. The samples were then cycled in a QuantStudio 7 flex qPCR instrument (Applied Biosystems) at 50
°C for 2 min, 95 °C for 20 s, 95 °C for 1 min, 60 °C for 20 s for 40 × cycles. Reaction volumes were 20ul. To ensure
comparable Ct values across plates and assays, thresholds for fluorescence detection for both mitochondrial and
nuclear amplicons were set to 0.08.
mtDNAcn was calculated using the ΔCt method. The ΔCt was obtained by subtracting the average mtDNA
Ct values from the average nDNA Ct values. Relative mitochondrial DNA copies are calculated by raising 2 to
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the power of the ΔCt and then multiplying by 2 to account for the diploid nature of the nuclear genome. The
number of mtDNAcn = 2ΔCt × 2. Both ND1 and COX1 yielded highly correlated results and the average of both
amplicon pairs was used as mtDNAcn value for each sample.

Statistical analyses. The hazard ratios (HR) and 95% confidence for survival differences between highand low-expression tumors was obtained from http://kmplot.com. Statistical Package for the Social Sciences
(SPSS) version 25.0 and R version 3.6.3 were used to analyze all other data. All distributions were examined for
outliers and nonnormality. Log transformations were applied to normalize distributions where necessary. Mitochondrial markers were compared between benign and tumor data using analyses of variance (ANOVAs). ANOVAs were also used to examine overall differences in means of mitochondrial variables according to cancer stage
or histology. Pearson product moment correlations were calculated to assess relationships between psychosocial
variables and mitochondrial variables and between mitochondrial variables and IL-6. A 95% confidence interval
was generated for each correlation coefficient. Heatmaps were generated using Prism 8 (Graphpad) https://www.
graphpad.com/scientific-software/prism/.
Received: 16 February 2021; Accepted: 4 May 2021
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